diabetes

Lilly says retatrutide beats Ozempic in diabetes trial

Eli Lilly's experimental drug retatrutide lowered blood sugar more than Novo Nordisk's Ozempic and produced more than twice the weight loss in a Phase 3 trial of adults with type 2 diabetes, Lilly announced Wednesday. Lilly called the study, TRANSCEND-T2D-2,…

Lilly’s triple-agonist drug cuts weight 21% in diabetes trial

Eli Lilly announced on Tuesday that its experimental drug retatrutide helped adults with type 2 diabetes and obesity lose an average of nearly 21% of their body weight in a late-stage clinical trial, marking the largest weight reduction ever recorded…

Roche obesity drug drives 15.5% weight loss in diabetes trial

Roche announced on Tuesday that its experimental obesity drug enicepatide helped patients with type 2 diabetes achieve an average 15.5% body weight reduction and restored many to non-diabetic blood sugar levels in a mid-stage clinical trial, bolstering the Swiss drugmaker's…

Novo’s CagriSema tops Eli Lilly’s tirzepatide in new trial

Novo unveiled new clinical data on Monday showing its experimental obesity drug CagriSema delivered superior weight loss compared to a lower dose of Eli Lilly's tirzepatide, offering a rebound for the company after its next-generation treatment stumbled in a head-to-head…

Novo Nordisk beats Q2 forecasts, raises 2026 outlook

Novo Nordisk, the Danish maker of weight-loss drug Wegovy, reported second-quarter adjusted operating profit that exceeded analyst expectations on Tuesday and raised its full-year 2026 outlook for the second time this year, citing stronger-than-expected sales of its GLP-1 drugs for…

AstraZeneca obesity pill moves to Phase III after nearly 12% weight loss in mid-stage trials

AstraZeneca unveiled full results from two mid-stage trials of its experimental oral obesity drug elecoglipron on Monday at the American Diabetes Association's 2026 Scientific Sessions in New Orleans, revealing that the once-daily pill produced an average body weight reduction of…